April 16-19 | Stockholm, Sweden
April 16-19 | Stockholm, Sweden
April 16-19 | Stockholm, Sweden
April 16-19 | Stockholm, Sweden
April 16-19 | Stockholm, Sweden
Conflict of interest disclosures
| Presenter | Disclosure | Company | ||
|---|---|---|---|---|
| D. Anrold | Receipt of grants/research supports | AbbVie | ||
| D. Arnold | Honoria or consultation fees | AstraZeneca, Boston Scientific, Bristol Myers Squibb, CRA International, Gilead, Janssen Cilag, Merck Sharp & Dohme, onkowissen, Pierre Fabre Pharma, Seagen, Terumo, Sanofi (Genzyme) | ||
| D. Arnold | Participation in a company sponsored speaker's bureau | Amgen, Aptitude Health, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Clinical Care Options (CCO), Eisai, From Research to Practice, GSK, lmedex, lpsen, mci, MedAhead (Austria), Merck (Serono), Merck Sharp & Dohme, Pierre Fabre Pharma, PRMA Consulting, Roche, Sanofi (Genzyme), Seagen, Servier, Terumo, Viatris | ||
| D. Arnold | Other (roles as Assoc. Editor) | Elsevier (ESMO Open and Ann Oncol, Clin Colorect Cancer) | ||
| A. Barnacle | No potential conflict of interest | |||
| S. Bhoori | Honoria or consultation fees | Roche, AZ, Terumo, Boston Scientific | ||
| C. Binkert | Receipt of grants/research supports | Abbott | ||
| C. Binkert | Honoria or consultation fees | CTI Vascular, Biotronik | ||
| D. Breen | Honoria or consultation fees | Boston Scientific | ||
| D. Breen | Participation in a company sponsored speaker's bureau | Neuwave/Ethicon | ||
| L. Crocetti | Receipt of grants/research supports | Terumo | ||
| L. Crocetti | Honoria or consultation fees | AstraZeneca, Biomedical, GEM, Histosonics, Terumo | ||
| L. Crocetti | Participation in a company sponsored speaker's bureau | Angiodynamics, AstraZeneca, Boston Scientific, Cascination, Terumo, Varian | ||
| T. de Baère | Receipt of grants/research supports | Terumo, Quantum | ||
| T. de Baère | Honoria or consultation fees | Boston Scientific, Terumo, Guerbet, GE-Healthcare, Quantum | ||
| T. de Baère | Participation in a company sponsored speaker's bureau | Boston Scientific, Terumo, Guerbet | ||
| A. Denys | Receipt of grants/research supports | Cook | ||
| A. Denys | Honoria or consultation fees | Neuwave, Angiodynamics | ||
| D. Filippiadis | No potential conflict of interest | |||
| A. Hatzidakis | No potential conflict of interest | |||
| I. Keussen | No potential conflict of interest | |||
| M. Meijerink | Receipt of grants/research supports | Medtronic, Angiodynamics, Johnson & Johnson | ||
| M. Meijerink | Honoria or consultation fees | Medtronic, Angiodynamics, Johnson & Johnson | ||
| F. Orsi | Receipt of grants/research supports | Medtronic (CIEMAR) | ||
| F. Orsi | Participation in a company spondored speaker's bureau | Medtronic, IceCure, Johnson & Johnson | ||
| J. Palussière | Honoria or consultation fees | Boston Scientific | ||
| P. Pereira | Receipt of grants/research supports | Angiodynamics, Medtronic, Terumo, Boston Scientific | ||
| P. Pereira | Honoria or consultation fees | Terumo, Medtronic | ||
| P. Pereira | Participation in a company spondored speaker's bureau | Terumo, Medtronic | ||
| S. Rieken | No potential conflict of interest | |||